GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
In October, when GSK agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits | With a $2.2 billion ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...
But GSK is only looking at the business Walmsley said the “we don’t need it and we won’t overpay for it," - and also pledged that its most important division, pharma, would not lose out on ...
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
Associate Global Pharmaceutical Analyst at GlobalData. She added that GSK may be getting more bang per buck in terms of its R&D investment, with seven drugs in pre-registration phase compared with ...
Hosted on MSN2mon
‘I’m not trying to turn GSK into Google’: How GSK’s Silicon Valley veteran has transformed the pharma giant into a tech powerhouseGSK’s chief digital and technology officer (CDTO) worked for years at tech giants like Apple and Salesforce before making the switch to the increasingly tech-savvy pharmaceutical sector.
GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer. Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than ...
GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback